Today marks the first official agency warning about the possibility of these drugs—specifically Mounjaro—decreasing the effectiveness of oral contraceptives.

The tirzepatide Patient Information Leaflet advises that if you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.” ...

The mean decrease in waist circumference for those on tirzepatide was 18.4 cm/7.2 in, and for those on semaglutide it was 13 cm/5.1 in – 42% higher for tirzepatide.

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, according to findings from the SURMOUNT-5 trial. As Healio previously ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of treatment Tirzepatide users experienced greater waistline reduction (7. ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in adults with obesity but without diabetes. Over 72 weeks, tirzepatide ...

Overall, women had a 23.8% reduction in body weight with tirzepatide compared with an 18.0% reduction on semaglutide. For men, there was a 17.8% and 11.0% reduction in body weight on tirzepatide and ...

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 di ...

Unlike FDA-approved drugs, compounded tirzepatide won’t come with a package insert when the prescription is dispensed. It’s important to discuss using compounded tirzepatide with a doctor ...

Under the brand name Wegovy (Novo Nordisk), semaglutide was approved for chronic weight management in 2021, 2 and as Zepbound (Eli Lilly), tirzepatide was approved for the same indication in 2023 ...

"Tirzepatide, along with other GLP-1 receptor agonists, are showing real promise not only for weight loss, but also for helping people manage their health in smarter, more effective ways." ...

Sharp increases were seen in dispensations of tirzepatide (0.0 to 40.6%) and semaglutide (2.4 mg; 0.0 to 32.2%) among adults without diabetes but prescribed WLMs; the most frequently dispensed WLM ...